Location History:
- Wufeng Township, TW (2014)
- Taipei, TW (2015)
Company Filing History:
Years Active: 2014-2015
Title: Mei-Ying Liao: Innovator in Antibody Research
Introduction
Mei-Ying Liao is a prominent inventor based in Wufeng, Taiwan. She has made significant contributions to the field of biomedical research, particularly in the development of antibodies and methods for cellular reprogramming. With a total of 3 patents, her work has the potential to impact cancer treatment and regenerative medicine.
Latest Patents
One of her latest patents is focused on anti-epithelial cell adhesion molecule (EpCAM) antibodies and methods of use thereof. This patent discloses an isolated monoclonal antibody or an antigen-binding fragment characterized by its specific binding affinity to EpCAM, which is crucial for targeting cancer cells. The antibody has been shown to bind specifically to cancer cells such as oral cancer cells, nasopharyngeal cancer cells, colorectal cancer cells, and ovarian cancer cells, while showing no binding affinity to normal cells. Another significant patent involves EpCAM as a reprogramming factor for non-pluripotent cells. This patent outlines methods for inducing non-pluripotent cells to become pluripotent, along with the identification and isolation of induced pluripotent stem (iPS) cells.
Career Highlights
Mei-Ying Liao is affiliated with Academia Sinica, a leading research institution in Taiwan. Her work has garnered attention for its innovative approaches to cancer therapy and cellular reprogramming.
Collaborations
She has collaborated with notable researchers such as Han-Chung Wu and Pi-Chun Li, contributing to the advancement of knowledge in her field.
Conclusion
Mei-Ying Liao's innovative research and patents in antibody development and cellular reprogramming highlight her significant role in advancing biomedical science. Her contributions are paving the way for new therapeutic strategies in cancer treatment and regenerative medicine.